HF
TBPH icon

HRT Financial’s Theravance Biopharma TBPH Stock Holding History

HRT Financial’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.07M Sell
180,635
-148,041
-45% -$2.45M 0.01% 1447
2026
Q1 		$5.33M Buy
328,676
+95,824
+41% +$1.7M 0.01% 952
2025
Q4 		$4.36M Buy
232,852
+209,397
+893% +$3.47M 0.01% 842
2025
Q3 		$342K Sell
23,455
-35,375
-60% -$447K ﹤0.01% 2099
2025
Q2 		$648K Buy
58,830
+41,340
+236% +$402K ﹤0.01% 1490
2025
Q1 		$156K Buy
+17,490
New +$163K ﹤0.01% 2076
2024
Q3 		– Sell
-153,424
Closed -$1.3M – 3117
2024
Q2 		$1.3M Buy
153,424
+22,035
+17% +$199K 0.01% 897
2024
Q1 		$1.18M Buy
131,389
+53,170
+68% +$493K 0.01% 809
2023
Q4 		$879K Sell
78,219
-61,679
-44% -$621K 0.01% 1056
2023
Q3 		$1.21M Sell
139,898
-161,182
-54% -$1.56M 0.01% 872
2023
Q2 		$3.12M Buy
+301,080
New +$3.32M 0.03% 442
2022
Q4 		– Sell
-49,596
Closed -$502K – 3129
2022
Q3 		$502K Buy
49,596
+33,840
+215% +$317K 0.01% 1523
2022
Q2 		$142K Sell
15,756
-19,533
-55% -$180K ﹤0.01% 2350
2022
Q1 		$337K Sell
35,289
-2,264
-6% -$22.2K ﹤0.01% 2152
2021
Q4 		$414K Buy
+37,553
New +$327K ﹤0.01% 2040
2021
Q3 		– Sell
-16,150
Closed -$234K – 3744
2021
Q2 		$234K Buy
16,150
+6,320
+64% +$119K ﹤0.01% 2303
2021
Q1 		$200K Buy
+9,830
New +$187K ﹤0.01% 2312
2020
Q4 		– Sell
-21,083
Closed -$311K – 2447
2020
Q3 		$311K Buy
21,083
+4,155
+25% +$77.8K 0.01% 1120
2020
Q2 		$355K Buy
+16,928
New +$435K 0.01% 915

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

HRT Financial's TBPH Position: Q2 2026 in Review

HRT Financial reduced its Theravance Biopharma (TBPH) stake by 45% in Q2 2026, selling an estimated $2.45M and leaving 180,635 shares worth $3.07M. The position accounts for 0.01% of the portfolio, ranked #1447.

HRT Financial first reported a position in TBPH in Q2 2020 and has held it in 19 quarters since. The position peaked at $5.33M in Q1 2026. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • HRT Financial held 180,635 shares of Theravance Biopharma worth $3.07M as of Q2 2026.
  • HRT Financial sold 148,041 Theravance Biopharma shares in Q2 2026, an estimated $2.45M.
  • Theravance Biopharma made up 0.01% of HRT Financial's portfolio in Q2 2026, its #1447 holding.
  • HRT Financial first reported a position in Theravance Biopharma in Q2 2020 and has held it in 19 quarters since.
  • HRT Financial's Theravance Biopharma position peaked at $5.33M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.